Skip to main content
MedPathMedPath Home
Clinical Trials/IRCT20170213032547N1
IRCT20170213032547N1
Completed
Phase 3

Effectiveness of Sofosbuvir/Daclatasvir for Treatment of People Who Inject Drug with HCV Infection in a Community-based Setting

Kerman University of Medical Sciences0 sites110 target enrollmentTBD
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit

Overview

Phase
Phase 3
Intervention
Not specified
Conditions
Not specified
Sponsor
Kerman University of Medical Sciences
Enrollment
110
Status
Completed
Last Updated
6 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
6 years ago
Study Type
Interventional
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • •Being male or female (including transgender)
  • •Being 18 years or older at the time of baseline interview
  • •Self\-reported drug injection with verification for non\-medical purposes in the past twelve months
  • •Having chronic infection of HCV as confirmed by HCV\-RNA
  • •Having lived for at least six months in Kerman and have no plan to move out for another three months
  • •Having written informed consent to participate in the study
  • •Understanding the Farsi language

Exclusion Criteria

  • •HBV/HCV Coinfection
  • •Pregnant woman
  • •TB/HCV Coinfection
  • •eGFR\<30 mL/min or chronic renal failure
  • •Drug\-drug interactions

Outcomes

Primary Outcomes

Not specified

Similar Trials

Recruiting
Phase 2
Efficacy & Safety of Sofosbuvir/Daclatasvir treatment in COVID-19: A randomized, controlled studyCOVID-19SARS-nCoV-2 infection
DRKS00022203PHARCO CORPORATE90
Completed
Phase 1
Efficacy of Daclatasvir+Sofosbuvir in patients with severe acute respiratory syndrome coronavirus (SARS-COVID-19)
IRCT20200816048422N1Ahvaz University of Medical Sciences70
Completed
Phase 3
Evaluation of the effect of sofosbuvir/daclatasvir in COVID-19 patientsCOVID-19.U07.1COVID-19
IRCT20200624047908N1Abadan University of Medical Sciences1,000
Completed
Phase 3
Efficacy of Daclatasvir and Sofosbuvir (Sovodak) in patients with HCV
IRCT20080901001155N30Rasht University of Medical Sciences16
Recruiting
Phase 2
Efficacy and safety of Sofosbuvir in the treatment of SARS-CoV-2: An Open Label phase II TrialSARS-CoV-2 ?associated SARI.SARS-CoV-2U07.1
IRCT20200328046882N1Shahid Beheshti University of Medical Sciences60